Propolis suppresses atopic dermatitis through targeting the MKK4 pathway
BioFactors · 2025
DOI: 10.1002/biof.2119 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, 2025. Verfasst von Ye-Ryeong Cho und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Yonsei University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Propolis, Dermatitis, Atopic, Filaggrin Proteins, MAP Kinase Kinase 4. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Rural Development Administration.
Abstract (Originalsprache)
Propolis is a natural resinous substance made by bees through mixing various plant sources. Propolis has been widely recognized as a functional food due to its diverse range of beneficial bioactivities. However, the therapeutic effects of consuming propolis against atopic dermatitis (AD) remain largely unknown. The current study aimed to investigate the potential efficacy of propolis against AD and explore the active compound as well as the direct molecular target. In HaCaT keratinocytes, propolis inhibited TNF‐α‐induced interleukin (IL)‐6 and IL‐8 secretion. It also led to a reduction in chemokines such as monocyte chemoattractant protein‐1 (MCP‐1) and macrophage‐derived chemokine (MDC), while restoring the levels of barrier proteins, filaggrin and involucrin. Propolis exhibited similar effects in AD‐like human skin, leading to the suppression of AD markers and the restoration of barrier proteins. In DNCB‐induced mice, oral administration of propolis attenuated AD symptoms, improved barrier function, and reduced scratching frequency and transepidermal water loss (TEWL). In addition, propolis reversed the mRNA levels of AD‐related markers in mouse dorsal skin. These effects were attributed to caffeic acid phenethyl ester (CAPE), the active compound identified by comparing major components of propolis. Mechanistic studies revealed that CAPE as well as propolis could directly and selectively target MKK4. Collectively, these findings demonstrate that propolis may be used as a functional food agent for the treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Department of Food Technology and Nutrition, Chonnam National University, Yeosu, Republic of Korea.
- College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- Department of Food Science and Biotechnology, Gachon University, Seongnam, Republic of Korea.
- Department of Agrobiology, Division of Apiculture, National Institute of Agricultural Sciences, Wanju, Republic of Korea.
- POSTECH Biotech Center, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.
ORCID-Profile: Taegun Kim, Sanguine Byun
Förderung
- National Research Foundation of Korea
- Rural Development Administration
Zitieren
APA
Cho, Y. R., Han, E. J., Heo, E., Jayasinghe, A. M. K., Won, J., Lee, S., Kim, T., Kim, S. K., Lim, S., Woo, S. O., Han, G., Kang, W., Ahn, G., & Byun, S. (2025). Propolis suppresses atopic dermatitis through targeting the MKK4 pathway. BioFactors. https://doi.org/10.1002/biof.2119
Vancouver
Cho YR, Han EJ, Heo E, Jayasinghe AMK, Won J, Lee S, et al. Propolis suppresses atopic dermatitis through targeting the MKK4 pathway. BioFactors. 2025. doi:10.1002/biof.2119
BibTeX
@article{Cho2025,
author = {Cho, Ye-Ryeong and Han, Eui Jeong and Heo, Eun and Jayasinghe, Arachchige Maheshika Kumari and Won, Jihyun and Lee, Soohwan and Kim, Taegun and Kim, Sung-Kuk and Lim, Seokwon and Woo, Soon Ok and Han, Gyoonhee and Kang, Wonku and Ahn, Ginnae and Byun, Sanguine},
title = {Propolis suppresses atopic dermatitis through targeting the MKK4 pathway},
journal = {BioFactors},
year = {2025},
doi = {10.1002/biof.2119}
}
EUVIMED